Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$11.3 million.

  • Cardiff Oncology's Net Income towards Common Stockholders rose 503.33% to -$11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.4 million, marking a year-over-year decrease of 1730.26%. This contributed to the annual value of -$45.5 million for FY2024, which is 962.26% down from last year.
  • According to the latest figures from Q3 2025, Cardiff Oncology's Net Income towards Common Stockholders is -$11.3 million, which was up 503.33% from -$13.9 million recorded in Q2 2025.
  • Over the past 5 years, Cardiff Oncology's Net Income towards Common Stockholders peaked at -$5.2 million during Q1 2021, and registered a low of -$13.9 million during Q2 2025.
  • Over the past 5 years, Cardiff Oncology's median Net Income towards Common Stockholders value was -$10.4 million (recorded in 2022), while the average stood at -$10.1 million.
  • Per our database at Business Quant, Cardiff Oncology's Net Income towards Common Stockholders crashed by 11213.11% in 2022 and then surged by 1079.35% in 2024.
  • Cardiff Oncology's Net Income towards Common Stockholders (Quarter) stood at -$9.4 million in 2021, then rose by 7.89% to -$8.7 million in 2022, then dropped by 7.35% to -$9.3 million in 2023, then fell by 26.22% to -$11.8 million in 2024, then rose by 4.49% to -$11.3 million in 2025.
  • Its Net Income towards Common Stockholders was -$11.3 million in Q3 2025, compared to -$13.9 million in Q2 2025 and -$13.4 million in Q1 2025.